PENTASA by Takeda is understood, but it appears to be a topical anti-inflammatory effect on colonic epithelial cells. First approved in 1993.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
PENTASA is an oral extended-release capsule formulation of mesalamine, an aminosalicylate indicated for inflammatory bowel disease maintenance and treatment. It works by delivering mesalamine directly to the colon to reduce inflammation in patients with ulcerative colitis and Crohn's disease. The extended-release mechanism allows for sustained therapeutic delivery throughout the GI tract.
As LOE approaches, the team will shift focus from growth to retention and lifecycle extension strategies, with potential for smaller focused teams.
understood, but it appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (i.e., prostanoids) and through the lipoxygenase pathways (i.e., leukotrienes and hydroxyeicosatetraenoic…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)
An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase
Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment
Mesalazine (PENTASA®) in Ulcerative Colitis
Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis
Worked on PENTASA at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPENTASA currently supports only 1 linked job opening, primarily at intern level in Business Development, reflecting the product's mature, declining lifecycle stage. Career opportunities are limited and focused on portfolio strategy rather than brand-building, making it a niche role for professionals interested in LOE management and competitive positioning.
1 open roles linked to this drug